Trial Profile
A Phase Ib Trial of Pembrolizumab (MK-3475) and Trametinib Focused on Advanced KRAS Mutant Non-small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Jun 2024.
- 06 Apr 2023 Planned End Date changed from 1 Jan 2023 to 1 Aug 2023.
- 01 Jun 2022 Planned End Date changed from 1 May 2022 to 1 Jan 2023.